Related references
Note: Only part of the references are listed.Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
Mridula Krishnan et al.
JCO ONCOLOGY PRACTICE (2022)
Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer
Jillian Phallen et al.
CANCER RESEARCH (2019)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit
Kathleen Kerrigan et al.
CLINICAL LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit
Chun-Ru Chien et al.
JOURNAL OF THORACIC DISEASE (2016)
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units
Anne-Claire Toffart et al.
INTENSIVE CARE MEDICINE (2015)
Intensive Care Unit Outcomes Among Patients With Lung Cancer in the Surveillance, Epidemiology, and End Results-Medicare Registry
Christopher G. Slatore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Lazarus Response in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
Corey J. Langer
JOURNAL OF CLINICAL ONCOLOGY (2009)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review
Lilian Minne et al.
CRITICAL CARE (2008)
Share Paper
